diabetes-congress-frankfurt-2019-scientifictracks

7 / 10

Page 30
Notes:
Joint Event
November 29-30, 2019 | Frankfurt, Germany
28th International Conference on 3rd International Conference on
Diabetes and Endocrinology Diabetes and Metabolism &
2
0
1
9 CONGRESS
DIABETES
2019
DIABETES
Journal of Diabetology | Volume 3
A Comparative study of muscle symptoms of atorvastatin with rosuvastatin in patients
of rtherosclerotic cardiovascular disease
Md Rakibul Hasan Rashed
Bangabandhu Sheikh Mujib Medical University, Bangladesh
Statins are the corner stone therapy of atherosclerotic
cardiovascular disease (ASCVD). Statin may cause myalgia,
myotoxicity, myopathy and rhabdomyolysis along with its
lipid lowering properties and pleiotropic effects. Statins
associated muscle symptoms (SAMS) are the leading cause of
nonadherent and discontinuation. This study was conducted
to evaluate and understand the muscle symptoms of high
intensity statin therapy (atorvastatin 40 mg and rosuvastatin
20 mg) for a period of three months in individual patient with
clinical atherosclerotic cardiovascular disease. A total of 280
patients with clinical atherosclerotic cardiovascular disease
werestudiedtooncedailyatorvastatin40mgandrosuvastatin
20 mg. It was a randomized controlled single blind trial. The
primaryendpointwasmusclesymptoms-musclepain,fatigue,
cramp/spasticity and weakness at 4 weeks and in 3months of
study period. Serum creatinine kinase was measured in every
patient with muscular symptoms. Patients of atorvastatin
group noticed severe pain more than rosuvastatin group
at the end of 4 weeks and 3 months of treatment period
respectively. Significantly more patients felt extremely bad
and bad with atorvastatin compared with rosuvastatin.
Patients of atorvastatin group showed more marked increase
muscle spasm than rosuvastatin group by spasticity grade.
Three patients of atorvastatin group developed grade
3 muscle power. Serum creatine kinase > 1500 U/L was
observed more in atorvastatin than rosuvastatin group. Statin
associated muscle symptoms (more severe muscle problem,
myositis/myopathy) observed more in atorvastatin than that
of rosuvastatin group. Both treatments were well tolerated.
No cases of rhabdomyolysis, incident diabetes, hepatic or
renal insufficiency were recorded during the study period.
Rosuvastatin had better outcome profile of muscle symptoms
than atorvastatin in patients with clinical atherosclerotic
cardiovascular disease among the Bangladeshi population.
Speaker Biography
Md Rakibul Hasan Rashed has completed my Doctor of Medicine in (MD)
in Cardiology in July, 2018 from Bangabandhu Sheikh Mujib Medical
University, Dhaka, Bangladesh. He is acting as Assistant Registrar in
Department of Cardiology, Rajshahi Medical College Hospital, Rajshahi,
Bangladesh. He has over 6 publications that have been citied over 10 times.
He is now working in a place where potential source of data exit regarding
different medical issues, specially cardiology and endocrine subject. He has
interest on research of medical science to contribute a bit in my sector.
e: